| scholarly article | Q13442814 |
| P50 | author | Federico Pulido | Q45357574 |
| John McKinnon | Q89398373 | ||
| Jose R. Arribas | Q37838345 | ||
| P2093 | author name string | Wei Shao | |
| John W Mellors | |||
| Rafael Delgado | |||
| P2860 | cites work | Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. | Q43707013 |
| Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. | Q44103766 | ||
| Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study | Q44624944 | ||
| A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. | Q46056602 | ||
| Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. | Q46059384 | ||
| HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review | Q46180060 | ||
| Polymorphisms in p1-p6/p6* of HIV Type 1 Can Delay Protease Autoprocessing and Increase Drug Susceptibility | Q46428758 | ||
| Protease inhibitor resistance update: where are we now? | Q46636705 | ||
| Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). | Q46775067 | ||
| Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy | Q46971899 | ||
| Cost-effectiveness analysis of enfuvirtide (ENF) added to an optimized therapy compared with an optimized therapy in patients with HIV/AIDS. | Q50668371 | ||
| Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. | Q51936440 | ||
| Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. | Q53570987 | ||
| Two-Months-off, Four-Months-on Antiretroviral Regimen Increases the Risk of Resistance, Compared with Continuous Therapy: A Randomized Trial Involving West African Adults | Q58827996 | ||
| Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice | Q80446898 | ||
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor | Q28368369 | ||
| Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors | Q28378860 | ||
| Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites | Q28379086 | ||
| Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss | Q28474984 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis | Q33592278 | ||
| Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. | Q35548279 | ||
| Paradoxes of adherence and drug resistance to HIV antiretroviral therapy | Q35715028 | ||
| Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. | Q36422805 | ||
| Benefits and concerns of simplification strategies in HIV-infected patients | Q36522617 | ||
| Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial | Q36627942 | ||
| The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors | Q36881276 | ||
| Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy | Q36900004 | ||
| Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors | Q37127869 | ||
| Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes | Q37189025 | ||
| Simplification strategies to reduce antiretroviral drug exposure: progress and prospects | Q37277829 | ||
| Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression | Q38404638 | ||
| CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial | Q38404888 | ||
| Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. | Q39579408 | ||
| Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients | Q39580564 | ||
| Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir | Q39601382 | ||
| Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro | Q39684211 | ||
| Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. | Q39843128 | ||
| A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. | Q40082978 | ||
| Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors | Q40763780 | ||
| Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. | Q42640549 | ||
| Characterization of gag and pol sequences from long-term survivors of human immunodeficiency virus type 1 infection | Q42671692 | ||
| Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir | Q42923011 | ||
| Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir | Q42931192 | ||
| Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). | Q43172783 | ||
| P433 | issue | 5 | |
| P921 | main subject | virology | Q7215 |
| P304 | page(s) | 725-732 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Antiviral Therapy | Q4775353 |
| P1476 | title | Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy | |
| P478 | volume | 16 |
| Q36811249 | Clinical implications of HIV-1 minority variants |
| Q50049305 | Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy |
| Q42174237 | Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes |
| Q36613143 | Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial |
| Q37987855 | Protease inhibitor monotherapy: what is its role? |
| Q33625191 | Single genome amplification of proviral HIV-1 DNA from dried blood spot specimens collected during early infant screening programs in Lusaka, Zambia |
| Q37454209 | Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency |
Search more.